AstraZeneca has announced the discontinuation of the phase III STABILIZE-CKD and DIALIZE-Outcomes trials for Lokelma (sodium zirconium cyclosilicate).

This decision was taken due to a significant increase in enrolment delays and low event rates. In the laboratory's view, these factors made it impossible to deliver study results in time to significantly advance clinical practice.

The STABILIZE-CKD and DIALIZE-Outcomes trials are part of the CRYSTALIZE evidence program, which includes clinical studies and real-world evidence examining the potential benefits of Lokelma in the management of hyperkalemia across the cardio-renal spectrum.

Despite the discontinuation of the trials, Lokelma is still approved for the treatment of a large population of patients with hyperkalemia in 56 countries.

AstraZeneca states that this decision does not result from safety concerns, and the positive benefit-risk ratio of Lokelma does not change in the approved indication.

Copyright (c) 2023 CercleFinance.com. All rights reserved.